“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy
- 13 May 2010
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 127 (2), 249-256
- https://doi.org/10.1002/ijc.25270
Abstract
The ability of cancer cells to escape from the natural or immunotherapy‐induced antitumor immune response is often associated with alterations in the tumor cell surface expression of Major Histocompatibility Complex (MHC) Class I antigens. Considerable knowledge has been gained on the prevalence of various patterns of MHC Class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data are available on the changes in MHC Class I expression happening during the course of cancer immunotherapy. We have recently proposed that the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy could be predetermined by the molecular mechanism responsible for the MHC Class I alteration and not by the type of immunotherapy used, i.e., interleukin‐2 (IL‐2), Bacillus Calmette‐Guèrin (BCG), interferon‐alpha (IFN‐α), peptides alone, dendritic cells loaded with peptides, protein‐bound polysaccharide etc. If the molecular alteration responsible for the changes in MHC Class I expression is reversible by cytokines (“soft” lesion), the MHC Class I expression will be upregulated, the specific T cell–mediated response will increase and the lesion will regress. However, if the molecular defect is structural (“hard” lesion), the MHC Class I expression will remain low, the escape mechanism will prevail and the primary tumor or the metastatic lesion will progress. According to this idea, the nature of the preexisting MHC Class I lesion in the cancer cell has a crucial impact determining the final outcome of cancer immunotherapy. In this article, we discuss the importance of these two types of molecular mechanisms of MHC Class I–altered expression.This publication has 67 references indexed in Scilit:
- The Janus face of dendritic cells in cancerOncogene, 2008
- Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding β2-microglobulin genesCancer Immunology, Immunotherapy, 2008
- Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanismsTissue Antigens, 2007
- Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanomaInternational Journal of Cancer, 2005
- Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumorsTissue Antigens, 2003
- DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomasCarcinogenesis: Integrative Cancer Research, 2001
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Natural history of HLA expression during tumour developmentImmunology Today, 1993
- In search of the ‘missing self’: MHC molecules and NK cell recognitionImmunology Today, 1990
- ISOLATION OF THE MHC GENES ENCODING THE TUMOUR‐SPECIFIC CLASS I ANTIGENS EXPRESSED ON A MURINE FIBROSARCOMAInternational Journal of Immunogenetics, 1986